Interpharm Holdings Inc - Amended Current report filing (8-K/A)
October 15 2007 - 12:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported)
October
15, 2007
Interpharm
Holdings, Inc.
(Exact
name of Registrant as specified in charter)
Delaware
|
0-22710
|
13-3673965
|
(State
or other
jurisdiction
of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
75
Adams Avenue, Hauppauge, New York
|
11788
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
(631)
952 0214
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Items
2.04 and 3.01
|
Triggering
Events that Accelerate or Increase a Direct Financial Obligation
or an
Obligation under an Off-Balance Sheet Arrangement and Notice of Failure
to
Satisfy a Continued Listing
Rule
|
As
disclosed in Interpharm Holdings, Inc.’s (“Holdings”) Current Report on Form 8-K
filed with the SEC on February 15, 2006 (the “February 8-K”), Interpharm, Inc.
(the "Company"), a wholly owned subsidiary of Holdings entered into a credit
agreement (the "Wells Fargo Credit Agreement") with Wells Fargo Bank, National
Association, acting through its Wells Fargo Business Credit operating division
("Wells Fargo"). Under the Wells Fargo Credit Agreement, the Company obtained
a
$41,500,000 credit facility from Wells Fargo. Copies of the Wells Fargo Credit
Agreement and related documents are annexed to the February 8-K.
As
of the
date of this Current Report, the Company is obligated to Wells Fargo under
the
Wells Fargo Agreement in the amount of approximately $32,500,000 (the “Outstanding Amount”)
and the Company has defaulted on certain of the financial covenants
contained in the Wells Fargo Agreement. As a result of these defaults,
Wells Fargo has the right to demand repayment of the Outstanding Amount. To
date, Wells Fargo has not demanded repayment of the Outstanding Amount and
Holdings and the Company are engaged in negotiations with Wells Fargo to amend
the Wells Fargo Credit Agreement and the covenants contained therein.
As
a
result of the negotiations with Wells Fargo, Holdings will not be able to file
its Form 10-K by its due date of October 15, 2007 and anticipates filing upon
the conclusion of negotiations with Wells Fargo. On October 12, 2007, Holdings
notified the American Stock Exchange (“AMEX”) that it would not file its Form
10-K in a timely manner in conformity with Section 610(b) of the AMEX Company
Guide.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
INTERPHARM
HOLDINGS, INC.
|
|
|
October
15, 2007
|
By:
/s/ Peter
Giallorenzo
|
|
Peter Giallorenzo
|
|
Chief Financial Officer and
Chief
Operating Officer
|
Interpharm (AMEX:IPA)
Historical Stock Chart
From Jan 2025 to Feb 2025
Interpharm (AMEX:IPA)
Historical Stock Chart
From Feb 2024 to Feb 2025